News for Rigel Pharmaceuticals, Inc. (RIGL)

PR NewswireSOUTH SAN FRANCISCO, Calif., May 22, 2025 Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and oth

Rigel Pharmaceuticals, Inc.'s 68% YoY revenue growth signals durable stock potential. Click for my RIGL earnings update and a look at my strategy.

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Rockwell Automation, Inc. ROK rose sharply during Wednesday...

Total Revenue: $53.3 million for Q1 2025.Net Income: $11.4 million for Q1 2025.Net Product Sales: $43.6 million, a 68% increase year-over-year.TAVALISSE Sales:

May 06, 2025 / 08:30PM GMTOperator Greetings and welcome to Rigel Pharmaceuticals financial conference call for the first-quarter 2025. (Operator Instructions)

The following slide deck was published by Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals reports strong Q1 2025 growth, with revenue up 68% YoY. Learn about their $200M+ guidance, robust pipeline, and market strategy.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsRay Furey - Executive Vice President,...

PR NewswireSOUTH SAN FRANCISCO, Calif., May 6, 2025 First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $4

Revenue: Achieved $53.3 million in total revenue for Q1 2025, surpassing the estimated $43.87 million.Net Income: Reported a net income of $11.4 million, a sig

Rigel Pharmaceuticals (RIGL) forecasts its net product sales to range between $185 million and $192 million for the fiscal year 2025. Additionally, the company

PR NewswireSOUTH SAN FRANCISCO, Calif., April 4, 2025 SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nas

PR NewswireSOUTH SAN FRANCISCO, Calif., March 10, 2025 SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIG

The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points.

Total Revenue for 2024: $145 million, a 39% increase over 2023.Net Product Sales for Q4 2024: $46.5 million, a 58% growth year over year.TAVALISSE Net Product

Mar 04, 2025 / 09:30PM GMTOperator Greetings, and welcome to Rigel Pharmaceuticals financial conference call for the fourth quarter and full year 2024. (Operato

Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireSOUTH SAN FRANCISCO, Calif., March 4, 2025 Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net prod

Quarterly Revenue: Achieved $57.6 million, surpassing the estimated $51.73 million.Quarterly EPS: Reported at $0.81, significantly exceeding the estimated $0.4